Secondary stroke prevention requires a comprehensive, etiology-based approach addressing antithrombotic therapy, vascular risk factor management, and lifestyle modification.
The approach to secondary stroke prevention includes lifestyle, modification, pharmacological treatment, and revascularization procedures for appropriately select patients.
Stroke subtype-specific considerations are critical for optimal secondary prevention.
Lifestyle modifications include smoking cessation,, exercise programs, dietary interventions along with anti-thrombotic therapies.
Trials have shown a benefit of short duration, dual anti-platelet therapy for the prevention of early recurrent stroke in patients with non-cardioembolic, minor ischemic, stroke or high risk TIA.
This recommendation is based on trials showing that early DAPT reduces recurrent stroke risk in the first weeks after minor stroke, when recurrence risk is highest.
Monotherapy with the aspirin or clopidogrel is usually continued after dual anti-platelet therapy, on the basis that continued therapy did not show superiority of long-term dual therapy of aspirin for late prevention.
Long-term aspirin monotherapy is recommended for treatment in patients with symptomatic large vessel, intracranial stenosis of 50 to 99%.
For patients with symptomatic large-vessel intracranial stenosis (50-99%), aspirin monotherapy is recommended for long-term treatment.
In patients with cryptogenic stroke, prolonged cardiac monitoring, leads to better detection of atrial fibrillation, than 24 hour monitoring.
In patients with nonvalvular atrial fibrillation, thrombin or factor 10A inhibition with a direct oral anticoagulants is first line therapy.
In patients with persistent or paroxysmal atrial fibrillation, direct oral anticoagulant (DOAC) therapy is appropriate.
Cardiac monitoring for occult atrial fibrillation is recommended in patients with cryptogenic stroke.
Prolonged cardiac monitoring with external or implantable monitors detects atrial fibrillation more effectively than 24-hour monitoring.
While biomarkers such as NT-proBNP have been associated with atrial fibrillation burden, they are not recommended in stroke guidelines.
DOACs are preferred over warfarin based on meta-analyses showing 19% lower pooled risk of stroke or systemic embolism driven primarily by a 50% reduction in hemorrhagic stroke without significantly lower ischemic stroke risk.
Multiple trials have established the safety of early DOAC initiation after ischemic stroke
A metaanalysis of randomized trials comparing direct oral anticoagulants with warfarin show the pooled risk of stroke or systemic embolism was 19% lower among patients treated with a direct oral anticoagulant.
The benefit was driven by a large reduction in the risk of hemorrhagic stroke without a significantly lower risk of ischemic stroke.
Antithrombotic therapy is tailored to stroke mechanism. For noncardioembolic TIA or minor stroke, dual antiplatelet therapy (DAPT) with aspirin and clopidogrel (300 mg loading dose, then 75 mg daily) or aspirin and ticagrelor (180 mg on day 1, then 90 mg twice daily) is recommended for 21 to 30 days, followed by long-term antiplatelet monotherapy with aspirin or clopidogrel.
Blood pressure management targets less than 130/80 mm Hg for most patients after ischemic stroke.
This target BP is supported by evidence showing blood pressure reduction prevents recurrent stroke, though the optimal timing of treatment initiation remains uncertain.
Lipid management aims for an LDL cholesterol goal of less than 70 mg/dL: intensive lipid lowering reduces recurrent vascular events in patients with atherosclerotic stroke.
Diabetes management in patients with type 2 diabetes targets a glycated hemoglobin level of less than 7%, along with lifestyle modifications, metformin therapy, and addition of either a GLP-1 agonist or SGLT2 inhibitor.
Carotid artery disease management includes revascularization for patients with severe stenosis ipsilateral to a nondisabling stroke or TIA who are candidates for intervention.
The choice between carotid endarterectomy and carotid artery stenting should be driven by patient comorbidities and vascular anatomy features.
In patients with carotid stenosis, stenting is associated with a higher risk of any stroke than carotid endarterectomy.
In contrast, patients with severe intracranial stenosis should not receive angioplasty and stenting as first-line therapy; aggressive medical management and short-term DAPT are preferred.
Patent foramen ovale (PFO) closure is considered reasonable in patients meeting specific criteria: age 18-60 years, nonlacunar stroke, no other identified cause, and high-risk PFO features.
Embolic stroke of uncertain source (ESUS) should not be treated empirically with anticoagulants or ticagrelor, as these were found to be of no benefit.
There is no indication for DOACs in patients with ESUS.
Vascular risk factor management extends beyond blood pressure and lipids.
Hypertension management is important, as 50-80% of patients have hypertension and treatment is highly effective, reducing recurrence risk by 30-40%.
Thiazide diuretics, angiotensin receptor blockers, or ACE inhibitors are prioritized based on trial evidence.
For lipid management in atherosclerotic ischemic stroke with LDL >100 mg/dL, atorvastatin 80 mg daily or rosuvastatin 20 mg daily is recommended.
If LDL <70 mg/dL cannot be achieved with statin monotherapy, adding ezetimibe or a PCSK9 inhibitor may be considered.
Lifestyle modifications play an essential role.
Low-salt and Mediterranean diets are recommended for stroke risk reduction.
Patients should be encouraged to perform physical activity in a supervised and safe manner, as they are especially at risk for sedentary behaviors.
Modifiable risk factors including diabetes, smoking cessation, lipids, and especially hypertension remain extremely important in secondary stroke prevention.